Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

por Nahar, Kazi J, Rawson, Robert V, Ahmed, Tasnia, Tattersall, Stephen, Sandanayake, Neomal, Kiely, Christopher J, Lo, Serigne, Carlino, Matteo, Palendira, Umaimainthan, Scolyer, Richard A, Long, Georgina V, Menzies, Alexander M
Publicado 2020

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

por Attrill, Grace Heloise, Owen, Carina N, Ahmed, Tasnia, Vergara, Ismael A, Colebatch, Andrew J, Conway, Jordan W, Nahar, Kazi J, Thompson, John F, Pires da Silva, Ines, Carlino, Matteo S, Menzies, Alexander M, Lo, Serigne, Palendira, Umaimainthan, Scolyer, Richard A, Long, Georgina V, Wilmott, James S
Publicado 2022

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis

por Nahar, Kazi J., Marsh-Wakefield, Felix, Rawson, Robert V., Gide, Tuba N., Ferguson, Angela L., Allen, Ruth, Quek, Camelia, da Silva, Ines Pires, Tattersal, Stephen, Kiely, Christopher J., Sandanayake, Neomal, Carlino, Matteo S., McCaughan, Geoff, Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Menzies, Alexander M., Palendira, Umaimainthan
Publicado 2022